FDA Advisory Committee recommends approval of DSUVIA for moderate-to-severe acute pain
AcelRx Pharmaceuticals announced the FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 10-3 in favor of recommending the approval of DSUVIA™ for management of moderate-to-severe acute pain in medically supervised settings for adult patients. October 12, 2018